Verona Pharma’s Ohtuvayre Set To Unlock Significant Value In COPD Care

Verona Pharma’s Ohtuvayre (ensifentrine) was approved for COPD in June 2024, introducing a novel dual mechanism of action. · Ohtuvayre is priced at …

Share on Facebook

Tweet

Follow us

Save